Pharmacokinetic variability of new antiepileptic drugs at different ages

Therapeutic Drug Monitoring

Volumn 27, Issue 6, 2005, Pages 714-717

  Perucca, Emilio ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Antiepileptic drugs; Children; Elderly; Infants; Pharmacokinetics; Review

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; DRUG METABOLITE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; MONOHYDROXYCARBAZEPINE; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AGE DISTRIBUTION; BACTERIAL FLORA; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MEGADOSE; EPILEPSY; HUMAN; INFANTILE SPASM; PRIORITY JOURNAL; STOMACH MOTILITY; AGING; ARTICLE; BIOAVAILABILITY; BLOOD; COMPARATIVE STUDY; METABOLIC CLEARANCE RATE;

AGING; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; HUMANS; METABOLIC CLEARANCE RATE;

EID: 33646827703     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000179847.37965.4e     Document Type: Conference Paper

References (45)

1. Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol. 2003;16:165-170.
2. Levy RH, Mattson RH, Meldrum BS, et al, eds. Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002.
3. Steward CF, Hampton EM. Effect of maturation on drug disposition in pediatric patients. Clin Pharm. 1987;6:548-564.
4. Bernus I, Dickinson RG, Hooper WD, et al. Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations. Drugs Aging. 1997;10:278-289.
5. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989;30:389-399.
6. Perucca E. The clinical pharmacokinetics of new generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet. 2005. (in press).
7. Morselli P, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants: age-related differences and therapeutic implications. Clin Pharmacokinet. 1980;5:485-527.
8. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167.
9. Perucca E. Drug metabolism in pregnancy, infancy and childhood. Pharmacol Ther. 1987;34:129-143.
10. Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet. 2000;38:271-290.
11. Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet. 1998;35:49-64.
12. Rey E, Pons G, Richard MO, et al. Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl-GABA) in epileptic children. Br J Clin Pharmacol. 1990;30:253-257.
13. Haig GM, Bockbrader HN, Wesche DL, et al. Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. J Clin Pharmacol. 2001;41:507-514.
14. Mikaeloff Y, Rey E, Soufflet C, et al. Topiramate pharmacokinetics in children with epilepsy aged 6 months to 4 years. Epilepsia. 2004;45:1448-1452.
15. Mikati MA, Fayad M, Koleilat M, et al. Efficacy, tolerability, and kinetics of lamotrigine in infants. J Pediatr. 2002;141:31-35.
16. Bartoli A, Guerrini R, Belmonte A, et al. The influence of dosage, age and comedication on steady-state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit. 1997;19:252-260.
17. Armijo JA, Bravo J, Cuadrado A, et al. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit. 1999;21:182-190.
18. Chen C, Casale EJ, Duncan B, et al. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. Pharmacotherapy. 1999;19:437-441.
19. Eriksson AS, Hoppu K, Nergardh A, et al. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia. 1996;37:769-773.
20. Battino D, Croci D, Granata T, et al. Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. Ther Drug Monit. 2001;23:217-222.
21. Rosenfeld WE, Doose DR, Walker SA, et al. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol. 1999;20:339-344.
22. Dahlin MG, Ohman IK. Age and antiepileptic drugs influence topiramate plasma levels in children. Pediatr Neurol. 2004;31:248-253.
23. Ferrari AR, Guerrini R, Gatti G, et al. Influence of dosage, age and comedication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit. 2003;25:700-708.
24. May TW, Rambeck B, Jurgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit. 2002;24:366-374.
25. Battino D, Croci D, Rossini A, et al. Topiramate pharmacokinetics in children and in adults with epilepsy: a case matched comparison based on therapeutic drug monitoring data. Clin Pharmacokinet. 2005;44(4):407-416.
26. Adin J, Gomez MC, Blanco Y, et al. Topiramate serum-concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Ther Drug Monit. 2004;26:251-257.
27. Sallas WM, Milosavljev S, D'souza J, et al. Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther. 2003;74:138-149.
28. Rey E, Bulteau C, Motte J, et al. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy. J Clin Pharmacol. 2004;44:1290-1300.
29. Ouellet D, Bockbrader HN, Wesche DL, et al. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res. 2001;47:229-241.
30. Gatti G, Ferrari AR, Guerrini R, et al. Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. Ther Drug Monit. 2003;25:54-60.
31. Armijo JA, Pena MA, Adin J, et al. Association between patient age and gabapentin serum concentration-to-dose ratio. A preliminary multivariate analysis. Ther Drug Monit. 2004;26:633-637.
32. Gustavson LE, Boellner SW, Granneman GR, et al. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology. 1997;48:1032-1037.
33. Pellock JM, Glauser TA, Bebin EM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia. 2001;42:1574-1579.
34. Miura H. Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. Seizure. 2004;13(Suppl 1):S17-S23.
35. Banfield CR, Zhu GRR, Jen JF, et al. The effect of age on the apparent clearance of felbamate: a retrospective analysis using non-linear mixed effect modeling. Ther Drug Monit. 1996;18:19-29.
36. Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharmacol Med. 1991;1:121-128.
37. Van Heiningen PNM, Eve MD, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther. 1991;50:410-419.
38. Arnoldussen W, Hulsman J, Rentmeester T. Oxcarbazepine (OCBZ) twice daily is as effective as OCBZ three times daily: a clinical and pharmacokinetic study in 24 volunteers and 6 patients. Epilepsia. 1991;32(Suppl 1):69.
39. Boyd RA, Turck D, Abel RB, et al. Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia. 1999;40:474-479.
40. Doose DR, Larson KL, Natarajan J, et al. Comparative single-dose pharmacokinetics of topiramate in elderly versus young men and women. Epilepsia. 1998;39(Suppl 6):56.
41. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707-724.
42. Snel S, Jansen JA, Mengel HB, et al. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy. J Clin Pharmacol. 1997;37:1015-1020.
43. Richens A, Banfield CR, Salfi M, et al. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol. 1997;44:129-134.
44. Haegele KD, Huebert ND, Ebel M, et al. Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clin Pharmacol Ther. 1988;44:558-565.
45. Shah J, Shellenberger K, Canafax D. Zonisamide: Chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds, Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams and Wilkins, 2002:872-84.